Outbreak of COVID-19 and SARS in mainland China: a comparative study based on national surveillance data

Author:

Zhao LinORCID,Feng Dan,Ye Run-Ze,Wang Hai-Tao,Zhou Yu-Hao,Wei Jia-Te,J. de Vlas SakeORCID,Cui Xiao-Ming,Jia Na,Yin Chao-Nan,Li Shi-Xue,Wang Zhi-QiangORCID,Cao Wu-Chun

Abstract

ObjectiveTo compare the epidemiological characteristics and transmission dynamics in relation to interventions against the COVID-19 and severe acute respiratory syndrome (SARS) outbreak in mainland China.DesignComparative study based on a unique data set of COVID-19 and SARS.SettingOutbreak in mainland China.ParticipantsThe final database included 82 858 confirmed cases of COVID-19 and 5327 cases of SARS.MethodsWe brought together all existing data sources and integrated them into a comprehensive data set. Individual information on age, sex, occupation, residence location, date of illness onset, date of diagnosis and clinical outcome was extracted. Control measures deployed in mainland China were collected. We compared the epidemiological and spatial characteristics of COVID-19 and SARS. We estimated the effective reproduction number to explore differences in transmission dynamics and intervention effects.ResultsCompared with SARS, COVID-19 affected more extensive areas (1668 vs 230 counties) within a shorter time (101 vs 193 days) and had higher attack rate (61.8 vs 4.0 per million persons). The COVID-19 outbreak had only one epidemic peak and one epicentre (Hubei Province), while the SARS outbreak resulted in two peaks and two epicentres (Guangdong Province and Beijing). SARS-CoV-2 was more likely to infect older people (median age of 52 years), while SARS-CoV tended to infect young adults (median age of 34 years). The case fatality rate (CFR) of either disease increased with age, but the CFR of COVID-19 was significantly lower than that of SARS (5.6% vs 6.4%). The trajectory of effective reproduction number dynamically changed in relation to interventions, which fell below 1 within 2 months for COVID-19 and within 5.5 months for SARS.ConclusionsChina has taken more prompt and effective responses to combat COVID-19 by learning lessons from SARS, providing us with some epidemiological clues to control the ongoing COVID-19 pandemic worldwide.

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

BMJ

Subject

General Medicine

Reference45 articles.

1. WHO . Cumulative number of reported probable cases of SARS, 2003. Available: http://www.who.int/csr/sars/country/2003_07_11/en/index.html [Accessed 22 Sep 2020].

2. The SARS epidemic in mainland China: bringing together all epidemiological data;Feng;Trop Med Int Health,2009

3. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

4. WHO . WHO Director-General’s opening remarks at the media briefing on COVID-19 - 28 February 2020, 2020. Available: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-28-february-2020 [Accessed 3 May 2020].

5. WHO . Coronavirus disease 2019 (COVID-19) situation report – 99, 2020. Available: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-99-covid-19.pdf?sfvrsn=119fc381_2 [Accessed 28 Apr 2020].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3